Allergic Rhinitis Market: By Type (Seasonal, Perennial, and Occupational Rhinitis), By Treatment (Immunotherapy, Antihistamines, Decongestants, Vertebral Fusion, Corticosteroids, and Others), By Route of Administration (Oral, Parenteral, and Intranasal), By Form (Solid and Liquid), By Test (Skin Test, IgE RAST Test, and Complete Blood Count), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Stores), and Geography

The Allergic Rhinitis Market size was valued at USD 23,63.8 million in 2023 and is anticipated to grow at a CAGR of 4.1% over 2024-2030. Allergic rhinitis is a common medical condition characterized by inflammation of the nasal passages caused by an allergic reaction to airborne allergens such as pollen, dust mites, pet dander, and mold spores. The market for allergic rhinitis treatments includes various medications and therapies aimed at alleviating the symptoms associated with the condition, such as sneezing, nasal congestion, runny nose, itching, and post-nasal drip. Some common types of treatments in this market include antihistamines, decongestants, corticosteroids, intranasal anticholinergics, and immunotherapy. The market is driven by the prevalence of allergic rhinitis, which affects a significant portion of the global population, leading to a demand for effective and safe treatments.

For instance, per European Community Respiratory Health Survey recorded a prevalence of 10 to 41% in adults with allergic rhinitis in 2023. Additionally, the market is influenced by the seasonal nature of allergic rhinitis, with increased demand during peak allergy seasons. Pharmaceutical companies and biotechnology firms actively engage in research and development efforts to introduce new and improved treatments for allergic rhinitis, including novel drug formulations and allergy-specific immunotherapies. For instance, Merck launched clarinex (Desloratadine) for the treatment of allergic rhinitis. Furthermore, healthcare professionals play a crucial role in diagnosing and prescribing appropriate treatments to manage the condition effectively.

Allergic Rhinitis Market Key Developments:

• In July 2021, GlaxoSmithKline plc (GSK) received FDA approval for Nucala (Mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis.
• In June 2021, Bayer AG received FDA approval for Astepro Allergy (Azelastine HCI .15%) as an over the counter (OTC) product for the temporary relief of nasal congestion, runny nose, sneezing, and itchy nose due to hay fever or other upper respiratory allergies.